Join today and be part of the best free investment newsletter on the web where we focus on market moving news.
Genoptix Inc. (NASDAQ:GXDX) said Thursday its fourth-quarter profit rose 38 percent as demand for its diagnostic services increased.
The company said its profit grew to $7.4 million, or 41 cents per share, from $5.4 million, or 30 cents per share, a year earlier. Revenue climbed 45 percent to $49.1 million from $34 million. According to Thomson Reuters, analysts expected a smaller profit of 35 cents per share and revenue of $48.8 million.
Genoptix also said it entered a three-year partnership with health insurer Aetna Inc. Starting April 1, Genoptix will be part of Aetna's testing network and offer laboratory and diagnostic services to improve treatment for patients with cancers of the blood and bone marrow, such as leukemia and lymphoma.
You can contact us during market hours at 1-888-9-ClubGrand (1888-925-8247) or via email at staff@wallstreetgrand.com .Gerard@WallStreetGrand.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") including 2009 growth, revenue for the second quarter and year of 2009 and gross margin for the second quarter and year of 2009. Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the impact of intense competition, the continuation or worsening of current economic conditions and the condition of the domestic and global credit and capital markets.
Disclaimer:
Wall Street Grand LLC has not been compensated by the company for this press release and does not expect to be compensated in the future for any type of awareness. To read our full disclaimer clicks the link http://www.wallstreetgrand.com/disclosure.html.
